Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
| Price | $4.78 |
|---|---|
| Market cap | $127.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 3.71-8.74 |
| Beta | 1.78 |
Explore UNCY's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.